Analyst Bruce Jackson of Benchmark Co. maintained a Buy rating on Exact Sciences, with a price target of $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bruce Jackson has given his Buy rating due to a combination of factors including the recent launch of Exact Sciences’ Multi-Cancer Early Detection (MCED) test, Cancerguard. This test addresses a significant unmet need by targeting the 70% of cancers that currently lack a recommended screening solution, opening up a largely untapped $25 billion market. Additionally, the partnership with Quest Diagnostics enhances the test’s accessibility through numerous patient access sites and mobile services.
Furthermore, Exact Sciences has shown promising financial projections, with a raised price target of $60 per share, which aligns with the industry average for 2026 EV/Revenue estimates. The company’s revenue guidance for 2025 has been increased, reflecting confidence in its growth trajectory. The anticipated revenue for the third quarter is in line with consensus estimates, indicating stable performance. These factors collectively support the positive outlook and justify the Buy rating.